Biotech

All Articles

AstraZeneca posts information on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed a very early check out the efficiency of its own in-house antibody-drug c...

iTeos- GSK's TIGIT celebrity reveals meaningful improvement

.After introducing a period 3 launch based upon good midstage end results, iTeos and also GSK are ac...

More joint FDA can easily speed up uncommon condition R&ampD: record

.The FDA ought to be even more open and also collaborative to unleash a surge in approvals of unusua...

Zenas, MBX, Bicara head to Nasdaq in warm time for biotech IPOs

.It is actually an uncommonly active Friday for biotech IPOs, with Zenas BioPharma, MBX as well as B...

Atea's COVID antiviral falls short to stop hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually failed one more COVID-19 test, but the biotech still s...

Neurocrine's proposal to conserve mental illness possibility neglects

.Neurocrine Biosciences' mental illness plan pivot has actually failed. The biotech was actually inc...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has made an overdue entrance to the radioligand event, spending one hundred million european...

F 2G increases $100M for second attempt to obtain new antifungal to market

.After F2G's 1st try to acquire a brand-new lesson of antifungal to market was actually derailed by ...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 plans amid profitability pressures

.Moderna has pledged to reduce R&ampD investing by $1.1 billion by 2027. The decision to shrink the ...

Sanofi's $80M bet on Key dystrophy drug ends in period 3 lose big

.Simply four months after Sanofi bet $80 thousand in beforehand cash on Fulcrum Rehabs' losmapimod, ...